A Phase 2 interventional study of Pemigatinib and Pembrolizumab in Metastatic Urothelial Carcinoma and Unresectable Urothelial Carcinoma, sponsored by Incyte Corporation. Terminated at 79 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-04.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing pembrolizumab in Carcinoma, Transitional Cell — 9 open to participants now, 13 under way, 3 of them phase 3. pembrolizumab · Carcinoma, Transitional Cell.
Among the 28 studies testing pembrolizumab in Carcinoma, Transitional Cell, this one is the 22nd largest by enrollment, is one of 4 that started in 2020, is one of 19 in phase 2, and was the 13th registered.
632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.
Browse Carcinoma, Transitional Cell studies →9 of the 28 studies testing pembrolizumab in Carcinoma, Transitional Cell are open now, in 4 countries. Recruiting first, the newest first:
Fox Chase Cancer Center · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States, Canada, Korea, Republic of and 1 more country
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
University of Oklahoma · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 21 · Phase 3 3
First in 2015; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 50 across 499 interventional studies indexed under Carcinoma, Transitional Cell.
Median enrollment 31 across the 28 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 28 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
12 studies in Carcinoma, Transitional Cell by Incyte Corporation: none open now, none under way, none of them phase 3. Of 12 finished, 8 (67%) have results posted.
Among the 12 studies in Carcinoma, Transitional Cell by Incyte Corporation, this one is the 11th largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 2, and was the 9th registered.
Incyte Corporation’s Carcinoma, Transitional Cell studies by the year they started, since 2017.
3 of the studies testing pembrolizumab in Carcinoma, Transitional Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05406713Matthew GalskyPembrolizumab in Muscle-invasive Bladder Cancer | 2027-01-31 |
| NCT04724018Dana-Farber Cancer InstituteSacituzumab Govitecan Plus EV in Metastatic UC | 2027-02-01 |
| NCT05239624Memorial Sloan Kettering Cancer CenterEnfortumab Vedotin and Pembrolizumab in People With Bladder Cancer | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies testing pembrolizumab in Carcinoma, Transitional Cell, from their registry updates:
Among Incyte Corporation’s 12 in Carcinoma, Transitional Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination of pemigatinib (13.5 milligrams \[mg\] once a day orally) plus pembrolizumab (200 mg every 3 weeks \[Q3W\] intravenously \[IV\])
Drug: Pemigatinib · Drug: Pembrolizumab
Pemigatinib (13.5 mg once a day orally) alone
Drug: Pemigatinib
Either gemcitabine plus carboplatin or pembrolizumab as standard of care. Gemcitabine 1000 mg/meters squared (m\^2) IV over 30 minutes on Days 1 and 8, followed by carboplatin (dosed to target area under the concentration-time curve \[AUC\] of 5 mg/milliliters \[mL\]/minute \[min\] or 4.5 mg/mL/min if required per local guidelines) on Day 1 or 2 of each 3-week cycle. Pembrolizumab 200 mg IV on Day 1 of each 21-day treatment cycle for up to 35 cycles or disease progression.
Drug: Gemcitabine · Drug: Carboplatin
13.5 mg once a day orally
Also known as: INCB054828
200 mg Q3W intravenously
Also known as: Keytruda®
1000 mg/m\^2 IV over 30 minutes on Days 1 and 8 of each 3-week cycle
Dosed to target AUC of 5 mg/mL/min or 4.5 mg/mL/min if required per local guidelines on Day 1 or 2 of each 3-week cycle
Progression-free Survival (PFS)
PFS was defined as the time from the randomization date until the date of disease progression (as measured by a blinded independent central review \[BICR\] per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\]) or death due to any cause, whichever occurred first.
Time frame: up to 130 days
Overall Survival (OS)
OS was defined as the time from the date of randomization until death due to any cause.
Time frame: up to 225 days
Objective Response Rate (ORR)
ORR was defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 (as measured by BICR).
Time frame: up to 148 days
Duration of Response (DOR)
DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression (per RECIST v1.1) or death, whichever occurred first (as measured by BICR).
Time frame: up to 148 days
Number of Participants With Treatment-emergent Adverse Events
A treatment-emergent adverse event was defined as an adverse event that was either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until 30 days after the last dose of study drug.
Time frame: up to 178 days
EORTC QLQ-C30 Score
The European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) contains 30 items and measures 5 functional dimensions (i.e., physical, role, emotional, cognitive, and social), 3 symptom items (i.e., fatigue, nausea/vomiting, and pain), 6 single items (i.e., dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and a global health and quality of life scale. For each scale and single item, a linear transformation was applied to standardize the scores between 0 (worst) and 100 (best) as described in the EORTC QLQ-C30 Scoring Manual.
Time frame: up to 160 days
Change From Baseline in the EORTC QLQ-C30 Score
The European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) contains 30 items and measures 5 functional dimensions (i.e., physical, role, emotional, cognitive, and social), 3 symptom items (i.e., fatigue, nausea/vomiting, and pain), 6 single items (i.e., dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and a global health and quality of life scale. For each scale and single item, a linear transformation was applied to standardize the scores between 0 (worst) and 100 (best) as described in the EORTC QLQ-C30 Scoring Manual. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; up to 160 days
Number of Participants With the Indicated EQ-5D-5L Dimension Scores
The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The EQ-5D-5L descriptive system is composed of 5 dimensions (mobility, self-case, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 response levels, which are coded by single-digit numbers: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = unable to/extreme problems. The EQ-5D-5L also includes a graded (0 \[worst overall health\] to 100 \[best overall health\]) vertical visual analog scale that provides a quantitative measure of the participant's perception of their overall health.
Time frame: up to 160 days
Change From Baseline in the EQ-5D-5L EQ Visual Analog Scale Score
The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The EQ-5D-5L descriptive system is composed of 5 dimensions (mobility, self-case, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 response levels, which are coded by single-digit numbers: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = unable to/extreme problems. The EQ-5D-5L also includes a graded (0 \[worst overall health\] to 100 \[best overall health\]) vertical visual analog scale that provides a quantitative measure of the participant's perception of their overall health.
Time frame: Baseline; up to 160 days
This study was conducted (enrolled participants) at 7 sites located in France, Italy, Spain, and Japan.
| Milestone | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg |
|---|---|---|---|
| Started | 0 | 1 | 6 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 1 | 6 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 3 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 3 |
PFS was defined as the time from the randomization date until the date of disease progression (as measured by a blinded independent central review \[BICR\] per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\]) or death due to any cause, whichever occurred first.
| months | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg |
|---|---|---|---|
| Progression-free Survival (PFS) | — | 1.81 (NA to NA) | 2.12 (1.51 to NA) |
OS was defined as the time from the date of randomization until death due to any cause.
| months | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg |
|---|---|---|---|
| Overall Survival (OS) | — | NA (NA to NA) | NA (1.51 to NA) |
ORR was defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 (as measured by BICR).
| percentage of participants | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg |
|---|---|---|---|
| Objective Response Rate (ORR) | — | 0 | 0 |
DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression (per RECIST v1.1) or death, whichever occurred first (as measured by BICR).
No measurements were reported for this outcome.
A treatment-emergent adverse event was defined as an adverse event that was either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until 30 days after the last dose of study drug.
| Participants | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg |
|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events | — | 1 | 6 |
The European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) contains 30 items and measures 5 functional dimensions (i.e., physical, role, emotional, cognitive, and social), 3 symptom items (i.e., fatigue, nausea/vomiting, and pain), 6 single items (i.e., dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and a global health and quality of life scale. For each scale and single item, a linear transformation was applied to standardize the scores between 0 (worst) and 100 (best) as described in the EORTC QLQ-C30 Scoring Manual.
| scores on a scale | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus carboplatinGemcitabine 1000 mg/m^2 Plus Carboplatin |
|---|---|---|---|
| Appetite Loss, Baseline | — | 33.3 ± NA | 26.7 ± 36.51 |
| Appetite Loss, Cycle 3 Day 1 | — | — | 16.7 ± 23.57 |
| Appetite Loss, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Appetite Loss, Follow Up | — | — | 66.7 ± NA |
| Cognitive Functioning, Baseline | — | 66.7 ± NA | 66.7 ± 20.41 |
| Cognitive Functioning, Cycle 3 Day 1 | — | — | 91.7 ± 11.79 |
| Cognitive Functioning, Cycle 6 Day 1 | — | — | 66.7 ± NA |
| Cognitive Functioning, Follow Up | — | — | 83.3 ± NA |
| Constipation, Baseline | — | 0.0 ± NA | 40.0 ± 27.89 |
| Constipation, Cycle 3 Day 1 | — | — | 16.7 ± 23.57 |
| Constipation, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Constipation, Follow Up | — | — | 33.3 ± NA |
| Diarrhea, Baseline | — | 0.0 ± NA | 20.0 ± 44.72 |
| Diarrhea, Cycle 3 Day 1 | — | — | 0.0 ± 0.0 |
| Diarrhea, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Diarrhea, Follow Up | — | — | 33.3 ± NA |
| Dyspnea, Baseline | — | 0.0 ± NA | 26.7 ± 27.89 |
| Dyspnea, Cycle 3 Day 1 | — | — | 16.7 ± 23.57 |
| Dyspnea, Cycle 6 Day 1 | — | — | 33.3 ± NA |
| Dyspnea, Follow Up | — | — | 66.7 ± NA |
| Emotional Functioning, Baseline | — | 50.0 ± NA | 73.3 ± 19.00 |
| Emotional Functioning, Cycle 3 Day 1 | — | — | 87.5 ± 5.89 |
| Emotional Functioning, Cycle 6 Day 1 | — | — | 91.7 ± NA |
| Emotional Functioning, Follow Up | — | — | 100.0 ± NA |
| Fatigue, Baseline | — | 44.4 ± NA | 46.7 ± 36.35 |
| Fatigue, Cycle 3 Day 1 | — | — | 50.0 ± 39.28 |
| Fatigue, Cycle 6 Day 1 | — | — | 33.3 ± NA |
| Fatigue, Follow Up | — | — | 55.6 ± NA |
| Financial Difficulties, Baseline | — | 33.3 ± NA | 20.0 ± 18.26 |
| Financial Difficulties, Cycle 3 Day 1 | — | — | 16.7 ± 23.57 |
| Financial Difficulties, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Financial Difficulties, Follow Up | — | — | 0.0 ± NA |
| Global Health Status/Quality of Life (QoL), Baseline | — | 16.7 ± NA | 51.7 ± 31.95 |
| Global Health Status/QoL, Cycle 3 Day 1 | — | — | 66.7 ± 11.79 |
| Global Health Status/QoL, Cycle 6 Day 1 | — | — | 66.7 ± NA |
| Global Health Status/QoL, Follow Up | — | — | 50.0 ± NA |
| Insomnia, Baseline | — | 33.3 ± NA | 46.7 ± 38.01 |
| Insomnia, Cycle 3 Day 1 | — | — | 33.3 ± 47.14 |
| Insomnia, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Insomnia, Follow Up | — | — | 66.7 ± NA |
| Nausea and Vomiting, Baseline | — | 0.0 ± NA | 6.7 ± 9.13 |
| Nausea and Vomiting, Cycle 3 Day 1 | — | — | 8.3 ± 11.79 |
| Nausea and Vomiting, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Nausea and Vomiting, Follow Up | — | — | 16.7 ± NA |
| Pain, Baseline | — | 50.0 ± NA | 40.0 ± 43.46 |
| Pain, Cycle 3 Day 1 | — | — | 41.7 ± 11.79 |
| Pain, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Pain, Follow Up | — | — | 16.7 ± NA |
| Physical Functioning, Baseline | — | 73.3 ± NA | 65.3 ± 26.83 |
| Physical Functioning, Cycle 3 Day 1 | — | — | 33.3 ± 47.14 |
| Physical Functioning, Cycle 6 Day 1 | — | — | 66.7 ± NA |
| Physical Functioning, Follow Up | — | — | 40.0 ± NA |
| Role Functioning, Baseline | — | 66.7 ± NA | 56.7 ± 40.14 |
| Role Functioning, Cycle 3 Day 1 | — | — | 33.3 ± 47.14 |
| Role Functioning, Cycle 6 Day 1 | — | — | 66.7 ± NA |
| Role Functioning, Follow Up | — | — | 33.3 ± NA |
| Social Functioning, Baseline | — | 66.7 ± NA | 53.3 ± 36.13 |
| Social Functioning, Cycle 3 Day 1 | — | — | 66.7 ± 0.00 |
| Social Functioning, Cycle 6 Day 1 | — | — | 66.7 ± NA |
| Social Functioning, Follow Up | — | — | 83.3 ± NA |
The European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) contains 30 items and measures 5 functional dimensions (i.e., physical, role, emotional, cognitive, and social), 3 symptom items (i.e., fatigue, nausea/vomiting, and pain), 6 single items (i.e., dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and a global health and quality of life scale. For each scale and single item, a linear transformation was applied to standardize the scores between 0 (worst) and 100 (best) as described in the EORTC QLQ-C30 Scoring Manual. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| scores on a scale | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg |
|---|---|---|---|
| Appetite Loss, Cycle 3 Day 1 | — | — | -16.7 ± 23.57 |
| Appetite Loss, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Appetite Loss, Follow Up | — | — | 0.0 ± NA |
| Cognitive Functioning, Cycle 3 Day 1 | — | — | 33.3 ± 23.57 |
| Cognitive Functioning, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Cognitive Functioning, Follow Up | — | — | 33.3 ± NA |
| Constipation, Cycle 3 Day 1 | — | — | -33.3 ± 0.00 |
| Constipation, Cycle 6 Day 1 | — | — | -33.3 ± NA |
| Constipation, Follow Up | — | — | -33.3 ± NA |
| Diarrhea, Cycle 3 Day 1 | — | — | -50.0 ± 70.71 |
| Diarrhea, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Diarrhea, Follow Up | — | — | -66.7 ± NA |
| Dyspnea, Cycle 3 Day 1 | — | — | 0.0 ± 0.00 |
| Dyspnea, Cycle 6 Day 1 | — | — | 33.3 ± NA |
| Dyspnea, Follow Up | — | — | 33.3 ± NA |
| Emotional Functioning, Cycle 3 Day 1 | — | — | 12.5 ± 29.46 |
| Emotional Functioning, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Emotional Functioning, Follow Up | — | — | 41.7 ± NA |
| Fatigue, Cycle 3 Day 1 | — | — | -11.1 ± 15.71 |
| Fatigue, Cycle 6 Day 1 | — | — | 11.1 ± NA |
| Fatigue, Follow Up | — | — | -44.4 ± NA |
| Financial Difficulties, Cycle 3 Day 1 | — | — | 0.0 ± 0.00 |
| Financial Difficulties, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Financial Difficulties, Follow Up | — | — | -33.3 ± NA |
| Global Health Status/QoL, Cycle 3 Day 1 | — | — | 33.3 ± 35.36 |
| Global Health Status/QoL, Cycle 6 Day 1 | — | — | 16.7 ± NA |
| Global Health Status/QoL, Follow Up | — | — | 33.3 ± NA |
| Insomnia, Cycle 3 Day 1 | — | — | -16.7 ± 23.57 |
| Insomnia, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Insomnia, Follow Up | — | — | -33.3 ± NA |
| Nausea and Vomiting, Cycle 3 Day 1 | — | — | 0.0 ± 0.00 |
| Nausea and Vomiting, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Nausea and Vomiting, Follow Up | — | — | 0.0 ± NA |
| Pain, Cycle 3 Day 1 | — | — | -8.3 ± 58.93 |
| Pain, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Pain, Follow Up | — | — | -83.3 ± NA |
| Physical Functioning, Cycle 3 Day 1 | — | — | -26.7 ± 37.71 |
| Physical Functioning, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Physical Functioning, Follow Up | — | — | -13.3 ± NA |
| Role Functioning, Cycle 3 Day 1 | — | — | 0.0 ± 0.00 |
| Role Functioning, Cycle 6 Day 1 | — | — | 0.0 ± NA |
| Role Functioning, Follow Up | — | — | 33.3 ± NA |
| Social Functioning, Cycle 3 Day 1 | — | — | 41.7 ± 11.79 |
| Social Functioning, Cycle 6 Day 1 | — | — | 33.3 ± NA |
| Social Functioning, Follow Up | — | — | 66.7 ± NA |
The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The EQ-5D-5L descriptive system is composed of 5 dimensions (mobility, self-case, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 response levels, which are coded by single-digit numbers: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = unable to/extreme problems. The EQ-5D-5L also includes a graded (0 \[worst overall health\] to 100 \[best overall health\]) vertical visual analog scale that provides a quantitative measure of the participant's perception of their overall health.
| Participants | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg |
|---|---|---|---|
| Anxiety/Depression, Baseline — 1 | — | 0 | 3 |
| Anxiety/Depression, Baseline — 2 | — | 0 | 0 |
| Anxiety/Depression, Baseline — 3 | — | 1 | 1 |
| Anxiety/Depression, Baseline — 4 | — | 0 | 1 |
| Anxiety/Depression, Baseline — 5 | — | 0 | 0 |
| Anxiety/Depression, Cycle 4 Day 1 — 1 | — | — | 1 |
| Anxiety/Depression, Cycle 4 Day 1 — 2 | — | — | 0 |
| Anxiety/Depression, Cycle 4 Day 1 — 3 | — | — | 0 |
| Anxiety/Depression, Cycle 4 Day 1 — 4 | — | — | 0 |
| Anxiety/Depression, Cycle 4 Day 1 — 5 | — | — | 0 |
| Anxiety/Depression, Cycle 7 Day 1 — 1 | — | — | 1 |
| Anxiety/Depression, Cycle 7 Day 1 — 2 | — | — | 0 |
| Anxiety/Depression, Cycle 7 Day 1 — 3 | — | — | 0 |
| Anxiety/Depression, Cycle 7 Day 1 — 4 | — | — | 0 |
| Anxiety/Depression, Cycle 7 Day 1 — 5 | — | — | 0 |
| Anxiety/Depression, Follow Up — 1 | — | — | 1 |
| Anxiety/Depression, Follow Up — 2 | — | — | 0 |
| Anxiety/Depression, Follow Up — 3 | — | — | 0 |
| Anxiety/Depression, Follow Up — 4 | — | — | 0 |
| Anxiety/Depression, Follow Up — 5 | — | — | 0 |
| Mobility, Baseline — 1 | — | 0 | 1 |
| Mobility, Baseline — 2 | — | 0 | 2 |
| Mobility, Baseline — 3 | — | 1 | 2 |
| Mobility, Baseline — 4 | — | 0 | 0 |
| Mobility, Baseline — 5 | — | 0 | 0 |
| Mobility, Cycle 4 Day 1 — 1 | — | — | 0 |
| Mobility, Cycle 4 Day 1 — 2 | — | — | 1 |
| Mobility, Cycle 4 Day 1 — 3 | — | — | 0 |
| Mobility, Cycle 4 Day 1 — 4 | — | — | 0 |
| Mobility, Cycle 4 Day 1 — 5 | — | — | 0 |
| Mobility, Cycle 7 Day 1 — 1 | — | — | 0 |
| Mobility, Cycle 7 Day 1 — 2 | — | — | 1 |
| Mobility, Cycle 7 Day 1 — 3 | — | — | 0 |
| Mobility, Cycle 7 Day 1 — 4 | — | — | 0 |
| Mobility, Cycle 7 Day 1 — 5 | — | — | 0 |
| Mobility, Follow Up — 1 | — | — | 0 |
| Mobility, Follow Up — 2 | — | — | 0 |
| Mobility, Follow Up — 3 | — | — | 0 |
| Mobility, Follow Up — 4 | — | — | 0 |
| Mobility, Follow Up — 5 | — | — | 1 |
| Pain/Discomfort, Baseline — 1 | — | 0 | 2 |
| Pain/Discomfort, Baseline — 2 | — | 0 | 1 |
| Pain/Discomfort, Baseline — 3 | — | 1 | 0 |
| Pain/Discomfort, Baseline — 4 | — | 0 | 2 |
| Pain/Discomfort, Baseline — 5 | — | 0 | 0 |
| Pain/Discomfort, Cycle 4 Day 1 — 1 | — | — | 1 |
| Pain/Discomfort, Cycle 4 Day 1 — 2 | — | — | 0 |
| Pain/Discomfort, Cycle 4 Day 1 — 3 | — | — | 0 |
| Pain/Discomfort, Cycle 4 Day 1 — 4 | — | — | 0 |
| Pain/Discomfort, Cycle 4 Day 1 — 5 | — | — | 0 |
| Pain/Discomfort, Cycle 7 Day 1 — 1 | — | — | 0 |
| Pain/Discomfort, Cycle 7 Day 1 — 2 | — | — | 0 |
| Pain/Discomfort, Cycle 7 Day 1 — 3 | — | — | 1 |
| Pain/Discomfort, Cycle 7 Day 1 — 4 | — | — | 0 |
| Pain/Discomfort, Cycle 7 Day 1 — 5 | — | — | 0 |
| Pain/Discomfort, Follow Up — 1 | — | — | 0 |
| Pain/Discomfort, Follow Up — 2 | — | — | 0 |
| Pain/Discomfort, Follow Up — 3 | — | — | 1 |
| Pain/Discomfort, Follow Up — 4 | — | — | 0 |
| Pain/Discomfort, Follow Up — 5 | — | — | 0 |
| Self-care, Baseline — 1 | — | 0 | 3 |
| Self-care, Baseline — 2 | — | 1 | 0 |
| Self-care, Baseline — 3 | — | 0 | 2 |
| Self-care, Baseline — 4 | — | 0 | 0 |
| Self-care, Baseline — 5 | — | 0 | 0 |
| Self-care, Cycle 4 Day 1 — 1 | — | — | 0 |
| Self-care, Cycle 4 Day 1 — 2 | — | — | 1 |
| Self-care, Cycle 4 Day 1 — 3 | — | — | 0 |
| Self-care, Cycle 4 Day 1 — 4 | — | — | 0 |
| Self-care, Cycle 4 Day 1 — 5 | — | — | 0 |
| Self-care, Cycle 7 Day 1 — 1 | — | — | 0 |
| Self-care, Cycle 7 Day 1 — 2 | — | — | 1 |
| Self-care, Cycle 7 Day 1 — 3 | — | — | 0 |
| Self-care, Cycle 7 Day 1 — 4 | — | — | 0 |
| Self-care, Cycle 7 Day 1 — 5 | — | — | 0 |
| Self-care, Follow Up — 1 | — | — | 0 |
| Self-care, Follow Up — 2 | — | — | 0 |
| Self-care, Follow Up — 3 | — | — | 1 |
| Self-care, Follow Up — 4 | — | — | 0 |
| Self-care, Follow Up — 5 | — | — | 0 |
| Usual Activities, Baseline — 1 | — | 0 | 2 |
| Usual Activities, Baseline — 2 | — | 0 | 1 |
| Usual Activities, Baseline — 3 | — | 1 | 2 |
| Usual Activities, Baseline — 4 | — | 0 | 0 |
| Usual Activities, Baseline — 5 | — | 0 | 0 |
| Usual Activities, Cycle 4 Day 1 — 1 | — | — | 0 |
| Usual Activities, Cycle 4 Day 1 — 2 | — | — | 1 |
| Usual Activities, Cycle 4 Day 1 — 3 | — | — | 0 |
| Usual Activities, Cycle 4 Day 1 — 4 | — | — | 0 |
| Usual Activities, Cycle 4 Day 1 — 5 | — | — | 0 |
| Usual Activities, Cycle 7 Day 1 — 1 | — | — | 0 |
| Usual Activities, Cycle 7 Day 1 — 2 | — | — | 1 |
| Usual Activities, Cycle 7 Day 1 — 3 | — | — | 0 |
| Usual Activities, Cycle 7 Day 1 — 4 | — | — | 0 |
| Usual Activities, Cycle 7 Day 1 — 5 | — | — | 0 |
| Usual Activities, Follow Up — 1 | — | — | 0 |
| Usual Activities, Follow Up — 2 | — | — | 0 |
| Usual Activities, Follow Up — 3 | — | — | 0 |
| Usual Activities, Follow Up — 4 | — | — | 1 |
| Usual Activities, Follow Up — 5 | — | — | 0 |
The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The EQ-5D-5L descriptive system is composed of 5 dimensions (mobility, self-case, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 response levels, which are coded by single-digit numbers: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = unable to/extreme problems. The EQ-5D-5L also includes a graded (0 \[worst overall health\] to 100 \[best overall health\]) vertical visual analog scale that provides a quantitative measure of the participant's perception of their overall health.
| scores on a scale | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg |
|---|---|---|---|
| Baseline | — | 40 ± NA | 52 ± 30.54 |
| Cycle 4 Day 1 | — | — | 5 ± NA |
| Cycle 7 Day 1 | — | — | 5 ± NA |
| Follow Up | — | — | 30 ± NA |
Collected over up to 178 days. Deaths were monitored for up to 225 days. Treatment-emergent adverse events (TEAEs) were monitored for up to 178 days (for up to 30 days after last dose of study drug).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemigatinib 13.5 mg | — | — | — |
| Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg | 3/6 (50%) | 1/6 (16.7%) | 6/6 (100%) |
| Event | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg |
|---|---|---|---|
| Bone painMusculoskeletal and connective tissue disorders | — | 1/1 | 0/6 |
| COVID-19Infections and infestations | — | 0/1 | 1/6 |
| Event | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg |
|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | — | 1/1 | 1/6 |
| Aspartate aminotransferase increasedInvestigations | — | 1/1 | 0/6 |
| Erythema multiformeSkin and subcutaneous tissue disorders | — | 1/1 | 0/6 |
| HyperphosphataemiaMetabolism and nutrition disorders | — | 1/1 | 0/6 |
| HypertransaminasaemiaHepatobiliary disorders | — | 1/1 | 0/6 |
| StomatitisGastrointestinal disorders | — | 1/1 | 0/6 |
| ConstipationGastrointestinal disorders | — | 0/1 | 3/6 |
| AstheniaGeneral disorders | — | 0/1 | 2/6 |
| Blood alkaline phosphatase increasedInvestigations | — | 0/1 | 2/6 |
| MalaiseGeneral disorders | — | 0/1 | 2/6 |
No participants were enrolled in the pemigatinib 13.5 mg treatment arm.
| Age, Customized(Participants) | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg | Total |
|---|---|---|---|---|
| 57 to 84 years old | 0 | 1 | 6 | 7 |
| Sex: Female, Male(Participants) | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg | Total |
|---|---|---|---|---|
| Female | — | NA | 4 | NA |
| Male | — | NA | 2 | NA |
| Ethnicity (NIH/OMB)(Participants) | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | — | NA | 0 | NA |
| Not Hispanic or Latino | — | NA | 5 | NA |
| Unknown or Not Reported | — | NA | 1 | NA |
| Race (NIH/OMB)(Participants) | Pemigatinib 13.5 mg | Pemigatinib 13.5 mg Plus Pembrolizumab 200 mg | Gemcitabine 1000 mg/m^2 Plus Carboplatin or Pembrolizumab 200 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | — | NA | 0 | NA |
| Asian | — | NA | 3 | NA |
| Native Hawaiian or Other Pacific Islander | — | NA | 0 | NA |
| Black or African American | — | NA | 0 | NA |
| White | — | NA | 3 | NA |
| More than one race | — | NA | 0 | NA |
| Unknown or Not Reported | — | NA | 0 | NA |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from May 2020 to primary completion in Apr 2021, 11 months.
Results were first posted in May 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemigatinib · Pembrolizumab
Carcinoma, Transitional Cell →